Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1966 3
1968 1
1969 1
1970 5
1971 2
1972 2
1973 1
1974 6
1975 2
1976 1
1977 2
1978 4
1979 7
1980 4
1981 7
1982 12
1983 4
1984 9
1985 3
1986 12
1987 8
1988 11
1989 7
1990 14
1991 15
1992 6
1993 4
1994 16
1995 10
1996 12
1997 7
1998 14
1999 18
2000 11
2001 12
2002 10
2003 7
2004 13
2005 11
2006 12
2007 12
2008 16
2009 5
2010 17
2011 16
2012 27
2013 41
2014 39
2015 48
2016 46
2017 56
2018 72
2019 59
2020 55
2021 55
2022 35
2023 20
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

856 results

Results by year

Filters applied: . Clear all
Page 1
Pharmacological treatment of COPD - New evidence.
Pires N, Pinto P, Marçal N, Ferreira AJ, Rodrigues C, Bárbara C; GI DPOC Interest Group on Chronic Obstructive Pulmonary Disease. Pires N, et al. Pulmonology. 2019 Mar-Apr;25(2):90-96. doi: 10.1016/j.pulmoe.2018.10.005. Epub 2018 Nov 28. Pulmonology. 2019. PMID: 30502972 Free article. Review.
Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD.
Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, Thach C, Fogel R, Patalano F, Vogelmeier CF; FLAME Investigators. Wedzicha JA, et al. N Engl J Med. 2016 Jun 9;374(23):2222-34. doi: 10.1056/NEJMoa1516385. Epub 2016 May 15. N Engl J Med. 2016. PMID: 27181606 Free article. Clinical Trial.
Exacerbations and Real-World Outcomes After Single-Inhaler Triple Therapy of Budesonide/Glycopyrrolate/Formoterol Fumarate, Among Patients with COPD: Results from the EROS (US) Study.
Strange C, Tkacz J, Schinkel J, Lewing B, Agatep B, Swisher S, Patel S, Edwards D, Touchette DR, Portillo E, Feigler N, Pollack M. Strange C, et al. Int J Chron Obstruct Pulmon Dis. 2023 Oct 12;18:2245-2256. doi: 10.2147/COPD.S432963. eCollection 2023. Int J Chron Obstruct Pulmon Dis. 2023. PMID: 37849918 Free PMC article.
A phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6 μg and 160/18/9.6 μg using co-suspension delivery technology in moderate-to-very severe COPD: The ETHOS study protocol.
Rabe KF, Martinez FJ, Ferguson GT, Wang C, Singh D, Wedzicha JA, Trivedi R, St Rose E, Ballal S, McLaren J, Darken P, Reisner C, Dorinsky P. Rabe KF, et al. Respir Med. 2019 Oct-Nov;158:59-66. doi: 10.1016/j.rmed.2019.08.010. Epub 2019 Aug 22. Respir Med. 2019. PMID: 31605923 Free article. Clinical Trial.
An overview of glycopyrrolate/eFlow® CS in COPD.
Kerwin E, Ferguson GT. Kerwin E, et al. Expert Rev Respir Med. 2018 Jun;12(6):447-459. doi: 10.1080/17476348.2018.1476853. Epub 2018 May 28. Expert Rev Respir Med. 2018. PMID: 29774778 Review.
Pharmacology, toxicology and clinical safety of glycopyrrolate.
Chabicovsky M, Winkler S, Soeberdt M, Kilic A, Masur C, Abels C. Chabicovsky M, et al. Toxicol Appl Pharmacol. 2019 May 1;370:154-169. doi: 10.1016/j.taap.2019.03.016. Epub 2019 Mar 21. Toxicol Appl Pharmacol. 2019. PMID: 30905688 Review.
Glycopyrrolate and formoterol fumarate for the treatment of COPD.
Grillet PE, Le Souder C, Rohou J, Cazorla O, Charriot J, Bourdin A. Grillet PE, et al. Expert Rev Respir Med. 2021 Jan;15(1):13-25. doi: 10.1080/17476348.2020.1807946. Epub 2020 Oct 12. Expert Rev Respir Med. 2021. PMID: 32772582 Review.
856 results